Your treatment plan
As chronic leukaemia is a complex condition, it is usually treated by a team of different healthcare specialists working together. This type of team is known as a multidisciplinary team (MDTs).
Members of your MDT may include:
- a haemato-oncologist (a specialist in the non-surgical treatment of leukaemia using techniques such as chemotherapy)
- a haemato-pathologist (a specialist in the study of cancerous blood cells)
- a pharmacist
- a social worker
- a psychologist
- a specialist cancer nurse (who will serve as the first point of contact between you and the other members of the MDT)
- a counsellor
There are several factors that will need to be taken into account when deciding on your treatment. They include:
- your age
- the extent of your cancer
- the likely progression of your cancer
- the possible side effects of treatment
No one will rush you into making a decision about your treatment, and you are free to talk to as many people as you want to, including your partner, family and friends.
Many people find that it can be helpful to write a list of questions at home to ask the MDT. Your MDT will be able to recommend what they feel are the best treatment options for you, but ultimately the decision will be yours.
The treatment of chronic leukaemia when the condition is in its early stages will depend on what type of chronic leukaemia you have. However, the treatments for both chronic myeloid leukaemia and chronic lymphocytic leukaemia (CLL) in their advanced stage are more or less the same.
Treating early-stage chronic lymphocytic leukaemia
There is no current effective medical treatment for early-stage chronic lymphocytic leukaemia (CLL).
Because of their associated side effects, possible treatments for CLL are only recommended once you begin to experience symptoms, or the leukaemia progresses to a potentially serious stage.
Instead, a policy of "watchful waiting" is recommended. This means that you will have regular blood tests so that the progress of your condition can be carefully monitored.
Treating advanced chronic lymphocytic leukaemia
Chemotherapy
Once chronic lymphocytic leukaemia has progressed to a more advanced stage, chemotherapy is the next treatment.
Chemotherapy tablets are usually used first because they have fewer and milder side effects than chemotherapy injections. Side effects include:
- tiredness
- skin rash
- increased vulnerability to infection
Chemotherapy can weaken your immune system, which helps protect you against infection. This is known as being immunocompromised. See Chronic lymphocytic leukaemia – Complications for more information about this.
If your symptoms persist or get worse, chemotherapy injections (intravenous chemotherapy) will need to be used. Intravenous chemotherapy causes more side effects than chemotherapy tablets and they tend to be more severe.
Side effects include:
- nausea
- vomiting
- tiredness
- hair loss
- infertility
These side effects should resolve after your treatment has finished, although there is a risk that infertility could be permanent. See Chronic lymphocytic leukaemia – Complications for more information about possible infertility treatments.
Rituximab
Rituximab is a new type of medication that is increasingly being used in combination with chemotherapy to treat CLL. Rituximab is what is known as a monoclonal antibody.
Monoclonal antibodies are antibodies that are genetically engineered in a laboratory. They are designed to directly target and attack cancer cells. This is why monoclonal antibody therapy can be referred to as targeted therapy.
Rituximab works by targeting a protein that is found on the surface of cancer cells, and encouraging your immune system to attack the protein which, in turn, should kill the cancer cells.
Rituximab is administered directly into your vein over the course of several hours. This is known as an infusion.
Common side effects of rituximab include:
- flu-like symptoms, such as chills and a high temperature, while the medication is being given
- dizziness
- nausea
- vomiting
In rare cases, rituximab can cause severe allergic reactions in some people. This is known as an infusion reaction and it can be fatal if left untreated.
Most infusion reactions occur within 24 hours of the first time that someone begins treatment. Therefore, it is likely that you will be closely monitored once your treatment begins. If you start to experience the symptoms of an infusion reaction, such as shortness of breath or chest pain, anti-allergy medicines such as corticosteroids can be used to help relieve your symptoms.
Bendamustine
Another new medication for CLL is called bendamustine. Bendamustine works by damaging the DNA of cancerous cells which should stop the cells from growing and reproducing.
The National Institute for Health and Clinical Excellence (NICE) has recommended bendamustine as treatment option for people with advanced CLL who are unable to use traditional chemotherapy medication for health reason (for example, a widely used medication for the treatment of CLL called fludarabine is often not suitable for people with kidney disease).
Bendamustine is also given by infusion, two times a week over the course of four weeks. This cycle of treatment may then be repeated up to six times.
Common side effects of bendamustine include:
- increased vulnerability to infection
- feeling sick
- being sick
- a high temperature (fever) of or above 38C (100.4F)
- feeling tired all the time (fatigue)
Bone marrow and stem cell transplants
The only available cure for chronic lymphoblastic leukaemia is to have a bone marrow or stem cell transplant.
Before transplantation can take place, the person receiving the transplant has to have aggressive, high-dose chemotherapy and radiotherapy to destroy any cancerous cells in their body.
This can put enormous strain on the body and can cause significant side effects and potential complications. Transplantations have better outcomes if the donor has the same tissue type as the person who is receiving the donation. The best candidate to provide a donation is usually a brother or sister with the same tissue type.
Due to these issues, transplantations are usually only successful when they are carried out in children and young people, or older people in good health, and there is a suitable brother or sister who can provide a donation.
In most cases of chronic lymphocytic leukaemia, the potential risks of transplantation far outweigh any benefit. For example, the chances of an elderly person with advanced chronic leukaemia surviving a bone marrow transplant can be as low as one in five.
However, you may have specific individual circumstances that mean that the benefits of treatment do outweigh the risks.
See the A-Z topic about Bone marrow transplant for more on bone marrow and stem cell transplantation.
Deciding against treatment
As many of the treatments that are described in this section have unpleasant side effects that can affect your quality of life, you may decide against having a particular type of treatment.
This is entirely your decision and your MDT will respect any decision that you make. Pain relief and nursing care will be made available as and when you need it.
Clinical trials
In the UK, a number of clinical trials are currently underway that aim to find the best way of treating leukaemia. Clinical trials are studies that use new and experimental techniques to see how well they work in treating and possibly curing leukaemia.
However, you should be aware that there is no guarantee that the techniques that are being studied in the clinical trial will be more effective than current treatments.
Your care team will be able to let you know whether there are any clinical trials available in your area, as well as explaining the benefits and risks involved.